Morgan Stanley said Sarepta Therapeutics' (SRPT) appointment of biotech veteran Michael Severino as its new CEO is a ‘positive’ development, but the firm remains cautious in the near term due to ongoing challenges in its Duchenne muscular dystrophy (DMD) business.SRPT stock was up around 4% at the…
Sarepta appointed Michael Severino as Chief Executive Officer effective July 28, 2026, as Douglas Ingram departs the CEO post and the board.Original SEC Filing: Sarepta Therapeutics, Inc. [ SRPT ] - 8-K - Jul. 27, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verifying im…
Sarepta Therapeutics Inc. (SRPT) shares were in focus on Thursday after a new analyst upgrade as Wall Street keeps an eye on multiple potential catalysts and readthrough from Novartis AG (NVS).According to TheFly, analysts at Wolfe Research upgraded Sarepta to ‘Outperform’ from ‘Peer Perform,’ with…
